IL-6

Increased Mortality in Giant Cell Arteritis

Save

A population-based study from Ontario, Canada suggests an increased mortality risk in patients with giant cell arteritis (GCA), according to a recent report in Arthritis Care & Research.

A health administrative data study looked at 22,677 GCA patients (≥50 years of age)

ACR Updated Guideline on Vaccinations for Rheumatic Patients

Save

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

This guideline builds on past

The Approach to Difficult to Treat Rheumatoid Arthritis

Save

Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.

D2T-RA is defined by failure of at least two different mechanism of action

Social Media Questions (7.29.2022)

Save

Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.

1. 
   

   Study of 63 Thalassemia pts (50

Early, Aggressive and Seropositive (7.22.2022)

Save

Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.

Still’s Disease FAQs

Save

What is the classic 'triad' of Still's disease? Does it affect males and females equally? What are typical lab findings? Which drugs are effective at treating Still's, and as importantly, which ones are not? What about complications? Read on for these and other FAQs regarding Still's disease.

ICYMI: 2021 Rheumatology Year in Review

Save

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Two Week Twitter (6.17.2022)

Save

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.

1. 
   

   Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast

Not All RA Drug Classes Are Created Equal

Save

Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.

For one, patients using inhibitors of the Janus-associated kinase (JAK) pathway were more likely to stop them because of adverse

EULAR 2022 Top 10 Abstracts (6.10.2022)

Save

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz.  Speaking of social media

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

Save

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded

Polymyalgia rheumatica immunological puzzle further illustrated

Save

Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015)